241 related articles for article (PubMed ID: 25997881)
21. Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania.
Mbugi EV; Mutayoba BM; Malisa AL; Balthazary ST; Nyambo TB; Mshinda H
Malar J; 2006 Oct; 5():94. PubMed ID: 17076899
[TBL] [Abstract][Full Text] [Related]
22. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity.
Alifrangis M; Enosse S; Khalil IF; Tarimo DS; Lemnge MM; Thompson R; Bygbjerg IC; Rønn AM
Am J Trop Med Hyg; 2003 Dec; 69(6):601-6. PubMed ID: 14740875
[TBL] [Abstract][Full Text] [Related]
23. A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR.
Toma H; Imada Y; Vannachone B; Miyagi M; Kobayashi J; Uechi G; Pethuvang R; Manivong K; Phompida S; Sato Y
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):602-4. PubMed ID: 16124424
[TBL] [Abstract][Full Text] [Related]
24. Declining trend of Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant alleles after the withdrawal of Sulfadoxine-Pyrimethamine in North Western Ethiopia.
Tessema SK; Kassa M; Kebede A; Mohammed H; Leta GT; Woyessa A; Guma GT; Petros B
PLoS One; 2015; 10(10):e0126943. PubMed ID: 26431464
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
[TBL] [Abstract][Full Text] [Related]
26. Short report: molecular markers associated with Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in the Democratic Republic of Congo.
Cohuet S; Bonnet M; Van Herp M; Van Overmeir C; D'Alessandro U; Guthmann JP
Am J Trop Med Hyg; 2006 Jul; 75(1):152-4. PubMed ID: 16837723
[TBL] [Abstract][Full Text] [Related]
27. Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia.
Gebru-Woldearegai T; Hailu A; Grobusch MP; Kun JF
Am J Trop Med Hyg; 2005 Dec; 73(6):1131-4. PubMed ID: 16354825
[TBL] [Abstract][Full Text] [Related]
28. The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women.
Gutman J; Kalilani L; Taylor S; Zhou Z; Wiegand RE; Thwai KL; Mwandama D; Khairallah C; Madanitsa M; Chaluluka E; Dzinjalamala F; Ali D; Mathanga DP; Skarbinski J; Shi YP; Meshnick S; ter Kuile FO
J Infect Dis; 2015 Jun; 211(12):1997-2005. PubMed ID: 25564249
[TBL] [Abstract][Full Text] [Related]
29. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria.
Kyabayinze D; Cattamanchi A; Kamya MR; Rosenthal PJ; Dorsey G
Am J Trop Med Hyg; 2003 Sep; 69(3):247-52. PubMed ID: 14628939
[TBL] [Abstract][Full Text] [Related]
30. A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology.
Alifrangis M; Enosse S; Pearce R; Drakeley C; Roper C; Khalil IF; Nkya WM; Rønn AM; Theander TG; Bygbjerg IC
Am J Trop Med Hyg; 2005 Feb; 72(2):155-62. PubMed ID: 15741552
[TBL] [Abstract][Full Text] [Related]
31. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea.
Reeder JC; Rieckmann KH; Genton B; Lorry K; Wines B; Cowman AF
Am J Trop Med Hyg; 1996 Aug; 55(2):209-13. PubMed ID: 8780462
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of mutations associated with higher levels of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Car Nicobar Island and Assam, India.
Ahmed A; Lumb V; Das MK; Dev V; Wajihullah ; Sharma YD
Antimicrob Agents Chemother; 2006 Nov; 50(11):3934-8. PubMed ID: 16982787
[TBL] [Abstract][Full Text] [Related]
33. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
Mockenhaupt FP; Teun Bousema J; Eggelte TA; Schreiber J; Ehrhardt S; Wassilew N; Otchwemah RN; Sauerwein RW; Bienzle U
Trop Med Int Health; 2005 Sep; 10(9):901-8. PubMed ID: 16135198
[TBL] [Abstract][Full Text] [Related]
34. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.
Kublin JG; Dzinjalamala FK; Kamwendo DD; Malkin EM; Cortese JF; Martino LM; Mukadam RA; Rogerson SJ; Lescano AG; Molyneux ME; Winstanley PA; Chimpeni P; Taylor TE; Plowe CV
J Infect Dis; 2002 Feb; 185(3):380-8. PubMed ID: 11807721
[TBL] [Abstract][Full Text] [Related]
35. [Progress of researches on genes associated with sulfadoxine-pyrimethamine resistance in
Qi-Cheng Z; Feng L
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2019 Apr; 31(3):346-348. PubMed ID: 31544425
[TBL] [Abstract][Full Text] [Related]
36. Emergence of sulfadoxine-pyrimethamine resistance in Indian isolates of Plasmodium falciparum in the last two decades.
Kumar A; Moirangthem R; Gahlawat SK; Chandra J; Gupta P; Valecha N; Anvikar A; Singh V
Infect Genet Evol; 2015 Dec; 36():190-198. PubMed ID: 26319997
[TBL] [Abstract][Full Text] [Related]
37. Source of drug resistant Plasmodium falciparum in a potential malaria elimination site in Saudi Arabia.
Al-Farsi HM; Al-Hashami ZS; Bin Dajem SM; Al-Sheikh AA; Al-Qahtani A; Beja-Pereira A; Idris MA; Babiker HA
Infect Genet Evol; 2012 Aug; 12(6):1253-9. PubMed ID: 22709478
[TBL] [Abstract][Full Text] [Related]
38. Selection and synergy in Plasmodium falciparum.
Sims P; Wang P; Hyde JE
Parasitol Today; 1999 Apr; 15(4):132-4. PubMed ID: 10322332
[No Abstract] [Full Text] [Related]
39. Effects of point mutations in Plasmodium falciparum dihydrofolate reductase and dihydropterate synthase genes on clinical outcomes and in vitro susceptibility to sulfadoxine and pyrimethamine.
Bacon DJ; Tang D; Salas C; Roncal N; Lucas C; Gerena L; Tapia L; Llanos-Cuentas AA; Garcia C; Solari L; Kyle D; Magill AJ
PLoS One; 2009 Aug; 4(8):e6762. PubMed ID: 19707564
[TBL] [Abstract][Full Text] [Related]
40. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy.
Aubouy A; Jafari S; Huart V; Migot-Nabias F; Mayombo J; Durand R; Bakary M; Le Bras J; Deloron P
J Antimicrob Chemother; 2003 Jul; 52(1):43-9. PubMed ID: 12805261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
